Human Longevity Inc.

Human Longevity Inc. is a biotechnology company using biological data to create medicine that is headquartered in San Diego, California and was founded in 2013 by Craig Venter, Peter Diamandis, and Robert Hariri.

Human Longevity is developing a database on human genotypes and phenotypes to develop diagnostics and therapeutics against aging-related human diseases and conditions. Human Longevity Inc. databases are available to pharmaceutical, biotechnology and academic organizations.

They are developing cell-based therapeutics to address decline in endogenous stem cell function and also focus on cancer, diabetes, obesity, heart and liver diseases and dementia. The company performs sequencing and provides human genome sequencing and offers genomic analysis with predictive and preventative care, as well as cancer analysis, newborn screening and screening for rare and undiagnosed diseases. Human Longevity also provides personalized vaccines and cell therapies.

Introduction to Human Longevity.

One of the co-founders of Human Longevity is J. Craig Venter which played a large role in the Human Genome Project. Venter left the company in May 2018 and has been accused of misappropriation of trade secrets in a Human Longevity lawsuit filed against him. Venter emailed a statement to Quartz stating that the claims are without merit and that the J. Craig Venter Institute will defend against the allegations and also that Venter is still a shareholder at Human Longevity Inc.

On March 4, 2014 Human Longevity completed their series A funding round with $80 million in funding from Synthetic Genomics, OS Fund, Illumina Ventures, DFJ, Celgene, Tan Thay, and Daniel Curran.

On April 5, 2016 Human Longevity completed their series B funding round with $220 million in funding from Illimina Ventures (lead investor), OS Fund, StartUp Health, GE Ventures, DFJ, Celgene, and Amino Capital.